MedTrace Logo

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

NCT06419608 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 336

Last updated 2026-01-07

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Conditions

Interventions

DRUG

BHV-7000

BHV-7000 75 mg taken once daily for 6 weeks

DRUG

Placebo

Matching placebo taken once daily for 6 weeks

Sponsors & Collaborators

  • Biohaven Therapeutics Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-28
Primary Completion
2025-11-07
Completion
2025-11-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06419608 on ClinicalTrials.gov